Most sponsors think about clinical supply consulting as something that happens after the protocol is finalized — a logistics exercise that follows the science. That sequencing is one of the more costly assumptions in clinical operations. Protocol decisions made without supply expertise routinely create downstream complications that are expensive to fix, slow to unravel, and sometimes impossible to fully resolve mid-study.

The Problem Starts Earlier Than Most Teams Realize

By the time a protocol reaches the supply planning team, many of the decisions that shape supply complexity have already been locked in. Dosing frequency, stratification factors, the number of treatment arms, eligibility criteria that affect enrollment velocity — all of these have direct implications for how medication is manufactured, packaged, distributed, and managed across sites.

A stratification factor that looks clinically meaningful on paper may require a kit configuration that dramatically increases the number of SKUs in play. An eligibility criterion that narrows the patient population may extend the enrollment timeline by months, changing expiry calculations entirely. These are not supply problems — they are protocol problems with supply consequences, and they are much easier to address during design than after initiation.

What Early RTSM Involvement Actually Changes

When supply and randomization expertise is brought into protocol development early, the conversation shifts from reactive to generative. Instead of asking "how do we support this design?" the question becomes "is there a way to achieve the same scientific objective with a more operationally efficient structure?"

Sometimes the answer is no — the clinical rationale requires a complex design and the supply implications are simply a cost of doing the study correctly. But often there are equivalent alternatives that reduce kit complexity, simplify site dispensing, or make resupply more predictable without compromising the primary endpoint. Finding those alternatives at the protocol stage is far less disruptive than discovering them during implementation.

The Site Experience Is Part of the Equation

Site coordinators are the last point of contact between the supply system and the patient. A complex dispensing workflow — multiple kit types, multiple dispensing conditions, multiple decision points at the point of care — increases the probability of coordinator error and lengthens the time required at each patient visit.

Protocol simplification that reduces dispensing complexity is not just a supply efficiency gain. It is a site quality initiative. Protocols that sites find manageable tend to have better compliance, fewer protocol deviations, and more reliable data — which ultimately reflects in the regulatory submission.

What Good Advisory Engagement Looks Like

The most effective supply advisory work happens before the IRT build begins. That means having experienced RTSM professionals review draft protocols with a specific focus on randomization logic, supply implications, and site operability — not as a formality, but as a substantive design conversation.

Korio structures its advisory team engagement around exactly this kind of early collaboration. The same project managers who will support the study through execution are involved from protocol review forward — which means the institutional knowledge about why certain decisions were made travels with the team throughout the trial.

ICH Guidelines Already Point in This Direction

The ICH E8(R1) guideline on general considerations for clinical studies explicitly emphasizes building quality into study design rather than inspecting for it afterward. That principle applies directly to RTSM and supply planning. Early engagement with clinical supply consulting expertise is a practical implementation of that philosophy — one that reduces amendment risk, improves site experience, and produces studies that are more robust from the first patient visit to database lock.

The cost of supply consulting at the protocol stage is a fraction of the cost of managing supply complications mid-study. For any sponsor running more than one trial at a time, systematic early engagement is not an optional investment — it is a standard operating procedure worth building.